Fig. 7
FOSL1 the most promising switch gene as therapeutic target. a FOSL1 belongs to the network of 41 switch genes that have, among their negative nearest neighbors, the core set of neurodevelopmental TFs (OLIG2, POU3F2, SALL2, SOX2). c FOSL1 results as an unfavorable prognostic marker with a log-rank test p-value equal to 0.019 and an adjusted p-value for multiple testing (Benjamini-Hochberg correction) equal to 0.3. The survival analysis was performed by using Kaplan-Meier method based on the gene expression and clinical data of 161 unique GBM patients provided by TCGA. Patients were split according to a median separation into two groups (i.e. low- and high-risk groups refer to patients with expression levels lower than or greater than the 50th percentile of the distribution of FOSL1 expression values). b FOSL1 acts as putative repressor TF of the core set of neurodevelopmental TFs (OLIG2, POU3F2, SALL2, SOX2) in GBM cells. The panel depicts a schematic representation of FOSL1 consensus binding motif according to JASPAR